DNLI NASDAQ
Denali Therapeutics Inc.
1W: -0.5%
1M: -4.7%
3M: -4.4%
YTD: +18.6%
1Y: +35.1%
3Y: -34.1%
5Y: -64.2%
$18.64
-0.66 (-3.42%)
Weekly Expected Move ±7.0%
$16
$17
$19
$20
$21
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
-0.90
Bearish
0 bullish
0 neutral
1 bearish
Articles (24h)
1
Hourly Sentiment (24h)
0.00
Neutral
1 bullish
0 neutral
1 bearish
Articles (7d)
2
Daily Sentiment (7 Days)
Articles (51)
Denali Stock Dips as Biogen-Partnered Parkinson's Disease Study Fails
Hedge Fund Wagers $36 Million on Biotech Denali After First FDA Approval
DNLI Q1 Loss Narrower Than Expected, Avlayah Approval Boosts Prospects
Denali Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights
Nancy Pelosi Stock Tracker Highlights Claude's Pharma Earnings Play: 'Will Be Interesting To See How This One Plays Out'
Privium Fund Opens $5.07 Million Denali Stake Ahead of FDA Drug Approval
B. Metzler seel. Sohn & Co. AG Makes New $1.84 Million Investment in Denali Therapeutics Inc. $DNLI
DNLI Gains 25.4% Year to Date: Should You Buy, Sell or Hold the Stock?
Denali Therapeutics Inc. $DNLI Shares Acquired by Baillie Gifford & Co.
Q3 EPS Forecast for Denali Therapeutics Lifted by Analyst
Denali Stock Falls as Partner Takeda Ends Collaboration Deal
Arista Networks To Rally Around 43%? Here Are 10 Top Analyst Forecasts For Tuesday
Takeda Exits Dementia Drug Partnership With Denali Therapeutics - Here's Why
Capricorn Fund Managers Ltd Acquires New Position in Denali Therapeutics Inc. $DNLI
SG Americas Securities LLC Increases Stock Position in Denali Therapeutics Inc. $DNLI
Denali Therapeutics Inc. $DNLI Stake Increased by Aberdeen Group plc
Denali Therapeutics Inc. (NASDAQ:DNLI) Receives Average Rating of “Moderate Buy” from Analysts
Equities Analysts Offer Predictions for DNLI FY2027 Earnings
Denali Wins FDA Nod for Hunter Syndrome Drug, Stock Up
Arm Holdings To Rally Over 27%? Here Are 10 Top Analyst Forecasts For Thursday
FDA Clears Denali Therapeutics Drug As First Brain-Penetrating Biologic For Rare Disease
Denali gains on FDA approval of lead asset
Cantor Fitzgerald L. P. Makes New $653,000 Investment in Denali Therapeutics Inc. $DNLI
Denali Gains 11.8% in a Month: Buy, Sell or Hold the Stock?
HC Wainwright Brokers Raise Earnings Estimates for DNLI
DNLI Q4 Loss Narrower Than Expected, Hunter Syndrome Drug in Focus
Denali Therapeutics GAAP EPS of -$0.73 in-line
Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
Denali Therapeutics Inc. (NASDAQ:DNLI) Receives Consensus Recommendation of “Buy” from Analysts
Denali Therapeutics Inc. (DNLI) Shareholder/Analyst Call Transcript
Denali Therapeutics Presents Enzyme TransportVehicle™ Progress Across Three Clinical Programs for Treatment of Lysosomal Storage Disorders at 2026 WORLDSymposium™
Denali Therapeutics To Host Webcast Highlighting Presentations on Enzyme TransportVehicle™ Programs at the 2026 WORLDSymposium™
Denali Therapeutics Announces Data Presentations on Enzyme TransportVehicle™ Programs for Hunter Syndrome, Sanfilippo Syndrome Type A and Pompe Disease at Upcoming 2026 WORLDSymposium™
Head to Head Comparison: Ultragenyx Pharmaceutical (NASDAQ:RARE) and Denali Therapeutics (NASDAQ:DNLI)
SG Americas Securities LLC Invests $555,000 in Denali Therapeutics Inc. $DNLI
Denali Therapeutics Inc. (DNLI) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Denali Therapeutics (NASDAQ:DNLI) Insider Sells $284,097.00 in Stock
Denali Therapeutics Unveils Portfolio Goals for 2026, Stock Up
The New England Journal of Medicine Publishes Phase 1/2 Study of Denali Therapeutics' Tividenofusp Alfa (DNL310) for Hunter Syndrome (MPS II)
Denali Therapeutics Inc. (NASDAQ:DNLI) Given Consensus Rating of “Buy” by Brokerages
Denali Therapeutics Inc. (NASDAQ:DNLI) Receives Consensus Rating of “Buy” from Analysts
Denali: Maintaining Strong Buy Based On DNL126 Expansion As MPS IIIA Treatment
Denali Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
Denali Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants
Denali Enters Into a $275M Funding Deal With Royalty Pharma
Denali Therapeutics Inc. (DNLI) Analyst/Investor Day Transcript
Edgestream Partners L.P. Acquires New Stake in Denali Therapeutics Inc. $DNLI
Denali: Regulatory Delay Is A Strategic Opportunity
Creative Planning Buys 27,114 Shares of Denali Therapeutics Inc. $DNLI
Denali Therapeutics Inc. (NASDAQ:DNLI) Receives Consensus Rating of “Buy” from Brokerages
Denali Therapeutics Inc. (DNLI) Presents at Jefferies London Healthcare Conference 2025 Transcript